share_log

Oppenheimer Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $130

Benzinga Real-time News ·  May 9, 2022 09:15

Oppenheimer analyst Jay Olson maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target from $160 to $130.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment